Extended-infusion versus standard-infusion piperacillin-tazobactam for sepsis syndromes at a tertiary medical center

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 8, 2014, Pages 4470-4475

  Cutro, Scott R ^a,c   Holzman, Robert ^a   Dubrovskaya, Yanina ^b   Chen, Xian Jie Cindy ^b   Ahuja, Tania ^b   Scipione, Marco R ^b   Chen, Donald ^a   Papadopoulos, John ^b   Phillips, Michael S ^a   Mehta, Sapna A ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^c KAISER PERMANENTE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; PENICILLANIC ACID; PIPERACILLIN; PIPERACILLIN, TAZOBACTAM DRUG COMBINATION;

AGED; ANALOGS AND DERIVATIVES; COST BENEFIT ANALYSIS; DRUG EFFECTS; ECONOMICS; FEMALE; GRAM NEGATIVE BACTERIUM; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LENGTH OF STAY; MALE; MICROBIOLOGY; MORTALITY; PATHOGENICITY; PATHOLOGY; PHYSIOLOGY; PROCEDURES; RETROSPECTIVE STUDY; SEPSIS; SURVIVAL; SYNDROME; TERTIARY HEALTH CARE;

AGED; ANTI-BACTERIAL AGENTS; COST-BENEFIT ANALYSIS; FEMALE; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; INFUSIONS, INTRAVENOUS; LENGTH OF STAY; MALE; PENICILLANIC ACID; PIPERACILLIN; RETROSPECTIVE STUDIES; SEPSIS; SURVIVAL ANALYSIS; SYNDROME; TERTIARY HEALTHCARE;

EID: 84905392264     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02759-14     Document Type: Article

References (25)

1. Pop-Vicas AE, D'Agata EMC. 2005. The rising influx of multidrugresistant Gram-negative bacilli into a tertiary care hospital. Clin. Infect. Dis. 40:1792-1798. http://dx.doi.org/10.1086/430314.
2. Savard P, Perl TM. 2012. A call for action: managing the emergence of multidrug-resistant Enterobacteriaceae in the acute care settings. Curr. Opin. Infect. Dis. 25:371-377. http://dx.doi.org/10.1097/QCO.0b013e3283558c17.
3. Sievert DM, Ricks P, Edwards JR, Schneider A, Patel J, Srinivasan A, Kallen A, Limbago B, Fridkin S. 2013. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect. Control Hosp. Epidemiol. 34:1-14. http://dx.doi.org/10.1086/668770.
4. Harbarth S, Garbino J, Pugin J, Lew JRD, Pittet D. 2003. Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am. J. Med. 115:529-535. http://dx.doi.org/10.1016/j.amjmed.2003.07.005.
5. Kollef MH, Golan Y, Micek ST, Shorr AF, Restrepo MI. 2011. Appraising contemporary strategies to combat multidrug resistant Gram-negative bacterial infections: proceedings and data from the Gram-Negative Resistance Summit. Clin. Infect. Dis. 53(Suppl 2):S33-S55. http://dx.doi.org/10.1093/cid/cir475.
6. Drusano GL. 2004. Antimicrobial pharmacodynamics: critical interactions of 'bug and drug.' Nat. Rev. Microbiol. 2:289-300. http://dx.doi.org/10.1038/ nrmicro862.
7. Craig W. 1996. Antimicrobial resistance issues of the future. Diagn. Microbiol. Infect. Dis. 25:213-217. http://dx.doi.org/10.1016/S0732-8893(96) 00162-9.
8. Lodise TP, Lomaestro BM, Drusano GL. 2006. Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on β-lactam antibiotics. Pharmacotherap. 26:1320-1332. http://dx.doi.org/10.1592/phco.26.9. 1320.
9. Kim A, Sutherland CA, Kuti JL, Nicolau DP. 2007. Optimal dosing of piperacillin-tazobactam for the treatment of Pseudomonas aeruginosa infections: prolonged or continuous infusion? Pharmacotherap. 27:1490-1497. http://dx.doi.org/10.1592/phco.27.11.1490.
10. Kuti JL, Dandekar PK, Nightingale CH, Nicolau DP. 2003. Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem. J. Clin. Pharmacol. 43:1116-1123. http://dx.doi.org/10.1177/ 0091270003257225.
11. Mouton JW, Dudley MN, Cars O, Derendorf H, Drusano GL. 2005. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J. Antimicrob. Chemother. 55:601-607. http://dx.doi.org/10.1093/jac/dki079.
12. Butterfield J, Lodise T, Beegle S, Rosen J, Farkas J, Pai M. 2014. Pharmacokinetics and pharmacodynamics of extended-infusion piperacillin/ tazobactam in adult patients with cystic fibrosis-related acute pulmonary exacerbations. J. Antimicrob. Chemother. 69:176-179. http://dx.doi.org/10.1093/ jac/dkt300.
13. Lee GC, Liou H, Yee R, Quan CF, Neldner K. 2012. Outcomes of extended-infusion piperacillin-tazobactam: a retrospective analysis of critically ill patients. Clin. Ther. 34:2297-2300. http://dx.doi.org/10.1016/j. clinthera.2012.11.005.
14. Lodise TP, Jr, Lomaestro B, Drusano GL. 2007. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extendedinfusion dosing strategy. Clin. Infect. Dis. 44:357-363. http://dx.doi.org/10.1086/ 510590.
15. Patel GW, Patel N, Lat A, Trombley K, Enbawe S, Manor K, Smith R, Lodise TP, Jr. 2009. Outcomes of extended infusion piperacillin/tazobactam for documented Gram-negative infections. Diagn. Microbiol. Infect. Dis. 64:236-240. http://dx.doi.org/10.1016/j.diagmicrobio.2009.03.002.
16. Yost RJ, Cappelletty DM, RECEIPT Study Group. 2011. The Retrospective Cohort of Extended-Infusion Piperacillin-Tazobactam (RECEIPT) study: a multicenter study. Pharmacotherap. 31:767-775. http://dx.doi.org/10.1592/phco. 31.8.767.
17. Falagas ME, Tansarli GS, Ikawa K, Vardakas KZ. 2013. Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis. Clin. Infect. Dis. 56:272-282. http://dx.doi.org/10.1093/cid/cis857.
18. Horan TC, Andrus M, Dudeck MA. 2008. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am. J. Infect. Contro. 36:309-332. http://dx.doi.org/10.1016/j.ajic.2008.03.002.
19. Tomaselli F, Dittrich P, Maier A, Woltsche M, Matzi V, Pinter J, Nuhsbaumer S, Pinter H, Smolle J, Smolle-Juttner FM. 2003. Penetration of piperacillin and tazobactam into pneumonic human lung tissue measured by in vivo microdialysis. Br. J. Clin. Pharmacol. 55:620-624. http://dx.doi.org/10.1046/j. 1365-2125.2003.01797.x.
20. Boselli E, Breilh D, Cannesson M, Xuereb F, Rimmele T, Chassard D, Saux MC, Allaouchiche B. 2004. Steady-state plasma and intrapulmonary concentrations of piperacillin/tazobactam 4 g/0.5 g administered to critically ill patients with severe nosocomial pneumonia. Intensive Care Med. 30:976-979. http://dx.doi.org/10.1007/s00134-004-2222-8.
21. Jehl F, Muller-Serieys C, de Larminat V, Monteil H, Bergogne-Berezin E. 1994. Penetration of piperacillin-tazobactam into bronchial secretions after multiple doses to intensive care patients. Antimicrob. Agents Chemother. 38:2780-2784. http://dx.doi.org/10.1128/AAC.38.12.2780.
22. Frei CR, Hampton SL, Burgess DS. 2006. Influence of culture sitespecific MIC distributions on the pharmacokinetic and pharmacodynamic properties of piperacillin/tazobactam and piperacillin: a data analysis. Clin. Ther. 28:1035-1040. http://dx.doi.org/10.1016/j.clinthera.2006.07.004.
23. Huijts SM, van Werkhoven CH, Boersma WG, Buijs J, Buunk G, Compaijen CJ, van Elde LJ, Gisolf JE, van der Kam R, Kluytmans JA, Kuipers BA, Mager JJ, Oppedijk B, Palmen F, Prins JM, van Reemst B, Silbermann MH, van Tiel FH, van der Wall E, van der Werf TS, Bonten MJ. 2013. Guideline adherence for empirical treatment of pneumonia and patient outcome: treating pneumonia in the Netherlands. Neth. J. Med. 71:502-507.
24. Julian-Jimenez A, Palomo de los Reyes MJ, Parejo Miguez R, Lain-Teres N, Cuena-Boy R, Lozano-Ancin A. 2013. Improved management of community-acquired pneumonia in the emergency department. Arch. Bronconeumol. 49:230-240. http://dx.doi.org/10.1016/j.arbres.2012.12.008.
25. Micek S, Roubinian N, Heuring T, Bode M, Williams J, Harrison C, Murphy T, Prentice D, Ruoff B, Kollef M. 2006. Before-after study of a standardized hospital order set for the management of septic shock. Crit. Care Med. 34:2707-2713. http://dx.doi.org/10.1097/01.CCM.0000241151.25426.D7.